Skip to main content
BDSX
NASDAQ Industrial Applications And Services

Biodesix Reports Strong Q1 Revenue Growth, Reduced Net Loss, and Secures Capital with ATM Program and Debt Extension

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$12.19
Mkt Cap
$113.908M
52W Low
$3.436
52W High
$20.21
52W Position info
255% above low
Off High info
40% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BDSX has more than doubled off its 52-week low of $3.436.

Summary

Biodesix Inc. reported robust first-quarter 2026 results, with significant revenue growth and a reduced net loss, while also strengthening its financial position through a substantial at-the-market equity offering and an extended debt maturity.


Key Events · Earnings and Guidance · BDSX

  • Strong Q1 2026 Revenue Growth

    Total revenue increased 42% year-over-year to $25.6 million, with Diagnostic Tests revenue up 37% and Development Services revenue surging 99%.

  • Reduced Net Loss

    The company reported a net loss of $7.8 million, a 30% improvement compared to a $11.1 million net loss in Q1 2025.

  • Significant Capital Raise via ATM

    Biodesix raised $16.7 million in net proceeds from the sale of 1,771,103 common shares through its at-the-market program at a weighted average price of $9.72 per share.

  • Debt Maturity Extended

    The maturity date for the $50.0 million Perceptive Term Loan Facility was extended by one year to November 21, 2028, enhancing financial flexibility.


Analysis · BDSX · Industrial Applications And Services

The company demonstrated strong operational performance in Q1 2026, with total revenue increasing by 42% year-over-year, driven by substantial growth in both diagnostic testing and development services. This operational improvement led to a 30% reduction in net loss compared to the prior year. Concurrently, Biodesix significantly bolstered its liquidity by raising $16.7 million in net proceeds through its at-the-market equity program, which, while dilutive, provides crucial capital. Furthermore, the extension of the $50.0 million Perceptive Term Loan Facility's maturity date to November 2028 enhances financial flexibility and extends the company's cash runway. These combined factors indicate a positive trajectory for the company's financial health and operational execution.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BDSX was trading at $12.19 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $113.9M. The 52-week trading range was $3.44 to $20.21. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BDSX - Latest Insights

BDSX
Nov 12, 2026, 9:29 AM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $10.12
Real-time Price: $9.00 info
Change: -$1.12 (-11%) info
Market Cap: $98.466M info
BDSX
Nov 12, 2026, 9:29 AM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $10.12
Real-time Price: $9.00 info
Change: -$1.12 (-11%) info
Market Cap: $98.466M info
BDSX
Nov 06, 2026, 3:24 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $9.00 info
Change: -$2.61 (-22%) info
Market Cap: $98.466M info
BDSX
Nov 05, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.00
Real-time Price: $9.00 info
Change: -$7.00 (-44%) info
Market Cap: $98.466M info
BDSX
Nov 05, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.70
Real-time Price: $9.00 info
Change: -$9.70 (-52%) info
Market Cap: $98.466M info